297 related articles for article (PubMed ID: 9551222)
41. [Review of relationship between tumor necrosis factor genetic polymorphism and hematological malignancies].
Zhao HY; Chen YX
Ai Zheng; 2003 Feb; 22(2):216-20. PubMed ID: 12600304
[TBL] [Abstract][Full Text] [Related]
42. Twenty-five Zambians with leukaemias.
Fleming AF
East Afr Med J; 1989 Mar; 66(3):162-6. PubMed ID: 2591324
[TBL] [Abstract][Full Text] [Related]
43. Tumor M2-PK levels in haematological malignancies.
Oremek GM; Rox S; Mitrou P; Sapoutzis N; Sauer-Eppel H
Anticancer Res; 2003; 23(2A):1135-8. PubMed ID: 12820361
[TBL] [Abstract][Full Text] [Related]
44. [Study on correlation and clinical significance of superoxide dismutase (SOD) activity and content in 102 patients with leukemia].
Zhu CS; Zhang CY; Weng WQ
Zhonghua Zhong Liu Za Zhi; 1994 Jan; 16(1):39-42. PubMed ID: 8033747
[TBL] [Abstract][Full Text] [Related]
45. Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
van Besien H; Sassano A; Altman JK; Platanias LC
Leuk Lymphoma; 2013 Dec; 54(12):2601-5. PubMed ID: 23540342
[TBL] [Abstract][Full Text] [Related]
46. [The standard treatments for patients with hematological malignancies in Japan].
Ishizawa K
Gan To Kagaku Ryoho; 2007 May; 34(5):709-12. PubMed ID: 17496442
[TBL] [Abstract][Full Text] [Related]
47. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
48. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
[TBL] [Abstract][Full Text] [Related]
49. Continuous infusion chemotherapy with epirubicin and vincristine in relapsed and refractory acute leukemia.
Liso V; Specchia G; Pavone V; Capalbo S; Dione R
Acta Haematol; 1990; 83(3):116-9. PubMed ID: 2109448
[TBL] [Abstract][Full Text] [Related]
50. Medical diagnostic X-ray irradiation and risk of leukemia in urban adult population of Poland. II. Bone marrow dose distributions.
Gajewski AK; Rózycki Z; Słowikowska MG; Krzyzanowski M; Majle T
Rocz Panstw Zakl Hig; 1988; 39(5):337-43. PubMed ID: 3247568
[No Abstract] [Full Text] [Related]
51. 2-Chlorodeoxyadenosine: treatment of hairy cell leukemia, chronic lymphocytic leukemia, and lymphocytic lymphoma.
Piro LD
Semin Hematol; 1993 Oct; 30(4 Suppl 6):28-30. PubMed ID: 7908756
[No Abstract] [Full Text] [Related]
52. Multiple myeloma and chronic leukaemias in 2014: improved understanding of disease biology and treatment.
San-Miguel JF; Kantarjian HM
Nat Rev Clin Oncol; 2015 Feb; 12(2):71-2. PubMed ID: 25511190
[TBL] [Abstract][Full Text] [Related]
53. [Quantitative-kinetic aspects of granulocytic resistance to infection in hematologic systemic diseases with reference to antineoplastic chemotherapy].
Sommer S
Z Arztl Fortbild (Jena); 1988; 82(11):513-5. PubMed ID: 3176536
[No Abstract] [Full Text] [Related]
54. DLI or second transplant.
Greinix HT
Ann Hematol; 2002; 81 Suppl 2():S34-5. PubMed ID: 12611068
[TBL] [Abstract][Full Text] [Related]
55. Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.
Vasconcelos FC; Cavalcanti GB; Silva KL; de Meis E; Kwee JK; Rumjanek VM; Maia RC
Leuk Res; 2007 Apr; 31(4):445-54. PubMed ID: 16979236
[TBL] [Abstract][Full Text] [Related]
56. [Leukemias and malignant lymphomas in children].
Schmiegelow K
Ugeskr Laeger; 1999 Apr; 161(15):2191-5. PubMed ID: 10222813
[No Abstract] [Full Text] [Related]
57. Absence of BRAF V600E mutation in hematologic malignancies excluding hairy-cell leukemia.
Ping N; Wang Q; Wang Q; Dong S; Wu L; Xue Y; Ruan C; Wu D; Chen S
Leuk Lymphoma; 2012 Dec; 53(12):2498-9. PubMed ID: 22639828
[No Abstract] [Full Text] [Related]
58. Autoimmunity and second malignancy in large granular lymphocytic leukaemia.
Bassan R; Rambaldi A; Barbui T
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():149-50. PubMed ID: 2785424
[No Abstract] [Full Text] [Related]
59. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
[TBL] [Abstract][Full Text] [Related]
60. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray.
Belov L; de la Vega O; dos Remedios CG; Mulligan SP; Christopherson RI
Cancer Res; 2001 Jun; 61(11):4483-9. PubMed ID: 11389079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
